Chairman & CEO
Dr. Veerappan Subramanian has over 30 years of experience in the pharmaceutical industry, has developed and commercialized more than 200 specialty drug products, and is credited as a business pioneer in the area of generic pharmaceuticals. Prior to founding Somerset Therapeutics, he established the development and marketing companies Novel Laboratories and GAVIS Pharmaceuticals in 2008, developing over 100 ANDAs in the controlled drugs, semi-solids, and inhalations forms, commercializing revenues of over $100 million prior to acquisition by Lupin Pharmaceuticals in 2015. Prior to founding Novel and GAVIS, Dr.Subramanian founded Kali Laboratories in 1997, specializing in immediate release, modified release, and controlled drug products and filing over 50 ANDAs prior to its acquisition by Par Pharma in 2005. Prior to becoming an entrepreneur, Dr. Subramanian has held numerous executive and leadership positions at IVAX/Zenith Laboratories, Purepac, Johnson & Johnson, Richardson Vicks, and Squibb. Dr. Subramanian received his Ph.D. in Pharmacy from Rutgers University in 1981 and has both a Bachelors and a Masters in Pharmacy. He is a registered pharmacist in New York and New Jersey.
Dr. Ilango Subramanian is General Manager of Somerset Therapeutics, LLC. In this role, Dr.Subramanian has responsibility for all Technical Operations, Manufacturing, and Research & Development. Prior to joining Somerset, Dr.Subramanian held a number of leadership positions at Novel Laboratories and GAVIS Pharmaceuticals from 2010 to 2015 as Vice President, responsible for Corporate Development, Biopharmaceutics, Medical Affairs, and Project Management. As a cross-functional executive, Dr.Subramanian coordinated the Novel and GAVIS teams in development of over 100 drug products and commercialization of 25 drug products as well as creating strategic development alliances with R&D organizations in softgel and transdermal drug technologies. Prior to this, Dr.Subramanian served as a Project Manager at Publicis Healthcare and a Consultant for BGB Healthcare Group. Dr. Subramanian received a Doctor of Pharmacy from Rutgers University Ernest Mario School of Pharmacy in 2009 and a Masters in Business Administration from New York University Stern School of Business in 2014. He is a registered pharmacist in New Jersey.
Vice President, Quality & Regulatory Affairs
Scott Talbot joined Somerset Therapeutics in June of 2019 as the Vice President of Quality Assurance & Regulatory Affairs. In this role, Mr.Talbot manages all regulatory and quality operations within the company. Mr.Talbot brings to Somerset over 30 years of quality and compliance experience with extensive expertise in sterile facility compliance with the FDA. Before joining Somerset , Scott served as Vice President of Quality and Regulatory Affairs for Slayback Pharma. Prior to Slayback, Mr.Talbot held management positions at Baxter Healthcare, Bausch & Lomb Pharmaceuticals, Teva, and Actavis. He has worked closely with FDA district offices in Puerto Rico, Florida, Kansas, and New Jersey on behalf of facilities in those districts, successfully resolving issues raised by FDA warning letters sent to these facilities. Scott holds bachelor’s degrees in biology and chemistry from Illinois State University.
Vice President, R&D
Dr. Mandar Shah joined Somerset Therapeutics in April of 2017 as Vice President of Research and Development. Dr. Shah oversees all R&D functions at Somerset Therapeutics LLC and its affiliate company Wintac Ltd, including product development, analytical development, regulatory affairs and product selection. Mandar has previously worked as a research executive for large pharma companies Bristol-Myers Squibb (1991 to 1993), Alcon (1996 to 2004), Pfizer (2004 to 2006) and J&J (2006 to 2012) as well as generic companies Ranbaxy (1994 to 1995), Sentiss (2012 to 2016) and West-Ward (2016 to 2017). In a career spanning more than 20 years in the pharma industry, Dr. Shah has developed an extensive array of sterile products and sterile product intellectual property. He specializes in developing non-infringing, difficult-to-formulate, difficult to manufacture, and complex generic products. He is also an inventor of over 20 patents filed or granted at the US Patent and Trademark Office and has developed a niche expertise in the Evergreening of the Patents- improving bioavailability, stability, manufacturing processes, and other critical parameters of known drugs to create new intellectual property. Dr. Shah obtained a Ph.D. degree in Pharmaceutical Chemistry from The University of Kansas in 1991, an Masters degree in Pharmaceutics from The University of Louisiana in 1985 and a Bachelors in Pharmacy degree from The Gujarat University in 1981.
Chief Financial Officer
Arshad Kagalwalla joined Somerset Therapeutics, LLC in July2016 as Chief Financial Officer. Arshad has over 20 years of experience in Finance & Accounting and 15 years in the generic pharmaceutical industry. He is currently responsible for the accounting operations, financial planning and analysis, budgeting and forecasting, taxation and revenue management including contracts and pricing for Somerset. Prior to joining Somerset, Arshad was head of Finance and Accounting at Novel Laboratories and GAVIS Pharmaceuticals. He has also worked as an accounting executive for Par Pharmaceuticals and Kali Laboratories. Arshad spent the early part of his career in public accounting, receiving a CPA in 2004, and is a Chartered Accountant in India.